BBHC
ATRA icon

Brown Brothers Harriman & Co’s Atara Biotherapeutics ATRA Stock Holding History

Brown Brothers Harriman & Co’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5
Closed -$2K – 800
2016
Q4 		$2K Hold
5
– – ﹤0.01% 825
2016
Q3 		$3K Hold
5
– – ﹤0.01% 727
2016
Q2 		$3K Buy
+5
New +$2.4K ﹤0.01% 760

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Brothers Harriman & Co's ATRA Position: Q1 2017 in Review

Brown Brothers Harriman & Co sold out of Atara Biotherapeutics (ATRA) in Q1 2017, closing a stake of 5 shares — an estimated $2K sold.

Brown Brothers Harriman & Co first reported a position in ATRA in Q2 2016 and held it in 3 quarters. The position peaked at $3K in Q3 2016. 85 funds tracked by Wall St. Rank hold ATRA as of Q1 2017.

  • Brown Brothers Harriman & Co reported no remaining Atara Biotherapeutics position as of Q1 2017 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 5 Atara Biotherapeutics shares in Q1 2017, an estimated $2K.
  • Brown Brothers Harriman & Co first reported a position in Atara Biotherapeutics in Q2 2016 and held it in 3 quarters.
  • Brown Brothers Harriman & Co's Atara Biotherapeutics position peaked at $3K in Q3 2016.
  • 85 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2017, filed 12 May 2017.